Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

A Multicenter, Open-label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu

Patients will receive a maximum of 18 injections of dHER2 vaccine in a treatment schedule that will last for up to about a year, and thereafter there will be a follow-up period of about one more year.

Study Overview

• Status: Completed
• Conditions: Neoplasms, Breast
• Intervention / Treatment: Biological: GSK Biologicals' 719125

Detailed Description

This Phase I/II study will be conducted according to a multicenter, open-label design. At least 20 patients will receive the vaccine as first-line and at least 20 as second-line treatment. The treatment will comprise a maximum of 18 injections of dHER2 vaccine. Follow-up phase: This will commence with the end-of-treatment examination, followed by examinations three months, six months and twelve months after the last study vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Charleroi, Belgium, 6000
    • GSK Investigational Site
  • Hasselt, Belgium, 3500
    • GSK Investigational Site
  • Ottignies, Belgium, 1340
    • GSK Investigational Site
• Colombia
  • Bogotá, Colombia, 11001000
    • GSK Investigational Site
• France
  • Lyon Cedex 08, France, 69373
    • GSK Investigational Site
  • Montpellier Cedex 5, France, 34298
    • GSK Investigational Site
  • Paris Cedex 05, France, 75248
    • GSK Investigational Site
  • Saint-Cloud, France, 92210
    • GSK Investigational Site
  • Saint-Herblain, France, 44805
    • GSK Investigational Site
  • Toulouse cedex, France, 31052
    • GSK Investigational Site
  • Vandoeuvre-Les-Nancy, France, 54511
    • GSK Investigational Site
• Italy
  • Lazio
    • Roma, Lazio, Italy, 00133
      • GSK Investigational Site
  • Lombardia
    • Milano, Lombardia, Italy, 20141
      • GSK Investigational Site
• Peru
  • Lima, Peru, Lima 34
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion criteria:

• Female.
• At least 18 years of age.
• Written informed consent to participate in the study.

• Diagnosis of advanced breast cancer. Furthermore, for patients being considered for second-line study treatment only: The patient has received a first-line chemotherapy together with Herceptin - or Herceptin alone - for her metastatic breast disease meeting all of the following conditions:

  i) For patients who have received a first-line chemotherapy together with Herceptin:

• The administration of chemotherapeutic agent(s) has been stopped for at least 3 months, or will have been stopped for at least 3 months by the time of the first study vaccination, and
• The administration of Herceptin alone was maintained after chemotherapy.

ii) The last dose of Herceptin was given not less than 3 weeks before the study vaccination.

iii) The patient will not be given Herceptin during the trial.

• A tumor lesion from the patient biopsied before or during screening, shows either i) overexpression of the HER2 protein, as determined by IHC (result: IHC 3+), or ii) amplification of the HER2 gene as determined by FISH (at least 4-fold, i.e., at least 8 copies).
• For patients being considered for first-line study treatment only: The patient's metastatic disease affects the skin and/or the lymph nodes and/or the lungs, but no other organ (with the exception of asymptomatic bone lesions). For patients being considered for second-line study treatment only: The patient's metastatic disease may affect any organ(s) with the exception of the central nervous system (CNS).
• At least one measurable lesion.
• ECOG status of 0 or 1.
• Agree to use effective contraception for the duration of the study and statement not to plan to bear children in the future.
• Result of serum β-HCG pregnancy test at the screening visit is negative. (This does not apply to patients who are not of child-bearing potential)
• Adequate bone marrow reserve.
• Adequate renal function.
• Adequate hepatic function.
• Baseline LVEF measured by MUGA scan equal to or greater than the lower limit of normal for the radiology facility.
• Results of a viral screening tests (HCV, and HBV surface antigen) on samples taken at the screening visit are both negative.
• Investigator believes that the patient can and will comply with the requirements of the protocol.

The following condition applies to centers in France only: A subject will be eligible for inclusion in this study if he/she is either affiliated to or a beneficiary of a social security category. It is the investigator's responsibility to ensure and to document (in source document - patient notes) that the patient is either affiliated to or a beneficiary of a social security category.

Exclusion criteria:

For patients being considered for first-line study treatment only:

• Received any chemotherapy for metastatic breast disease.
• Received >300 mg/m2 doxorubicin (cumulative dose) or >600 mg/m2 epirubicin (cumulative dose).
• Although hormone therapy as a first-line therapy for metastatic disease is accepted, it must NOT have been started or modified (in nature or dosage) within the 12 weeks before the first study vaccination, and NO such change during the study period may be anticipated.
• Treatment with bisphosphonate UNLESS the bisphosphonate treatment was initiated more than 3 months before first study vaccination.
• Received any investigational or non-registered drug or vaccine other than the study vaccine within the 30 days preceding the first dose of study vaccine, or plans to receive such a drug during the study period.

• For patients being considered for first-line study treatment, any of the following will result in exclusion of the patient:

  1. Any organ other than skin, lymph nodes, bone and lung is affected by the metastatic disease.
  2. If the lung is affected: >3 lung lesions have been detected.
  3. If the lung is affected: Any lesion measures 30 mm or more (longest diameter).
  4. If the lung is affected: The lung metastases cause any functional impairment.
  5. The sponsor may during the study instruct sites that no further patients with lung metastases are to be included. Receipt of such instructions from the sponsor constitutes an exclusion criterion for all further patients with lung metastases.For patients being considered for second-line study treatment, the presence of lung metastases that cause any functional impairment following will result in exclusion of the patient.
• The patient has a history of congestive heart failure or difficult-to-control hypertension, hypercholesterolemia or diabetes.
• The patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction.
• The patient has any acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
• The patient presents with autoimmune disease.
• The patient requires chronic administration of immunosuppressive drugs including corticosteroids.
• Medical history includes splenectomy or irradiation to the spleen.
• Known family history of congenital or hereditary immunodeficiency.
• Received major organ graft (including bone-marrow transplantation).
• Any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or prothrombotic disorder.
• History of anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
• HIV positive.
• Previous or concomitant malignancies at other sites, except (i) effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix, and (ii) effectively treated malignancy that has been in remission for >2 years and which is considered highly likely to have been cured.
• Pregnant or lactating.
• Any psychiatric or addictive disorder that may compromise ability to give informed consent, or to comply with the trial procedures.
• Any history of alcohol or drug abuse.
• Any other condition is present that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with requirements of the study
• Received any commercial vaccine within one week before the first study vaccination.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A; Patients receive study vaccinations in 3 consecutive cycles: In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.; In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.; In Cycle 3, subjects will patients six vaccinations at three-week intervals.	Biological: GSK Biologicals' 719125; Patients receive six vaccinations at two-week intervals
Experimental: Group B; Patients receive study vaccinations as second-line therapy	Biological: GSK Biologicals' 719125; Patients receive six vaccinations at two-week intervals

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Vaccine-related Grade 3 or 4 toxicity (other than skin toxicity and influenza-like symptoms) according to the Common Terminology Criteria for Adverse Events version 3.0	During the study.
Objective clinical response (CR or PR)	At each tumor evaluation (Visits 7, 14 and 21)

Secondary Outcome Measures

Outcome Measure	Time Frame
Stable disease	At each tumor evaluation (Visits 7, 14 and 21)
Mixed response	At each tumor evaluation (Visits 7, 14 and 21)
Time to disease progression	At the time of analysis.
Time to onset of response, defined as time from first vaccination to the initial response	At the time of analysis.
The duration of overall response is measured from the time that measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented	At the time of analysis.
Anti-dHER2, anti-HER2 ECD and anti-HER2 ICD seropositivity.	At all point during treatment (as specified in the study schedule)
Functional activity in vitro	At all point during treatment (as specified in the study schedule)
Frequency of cellular immune response in vitro to dHER2, HER2 ECD and HER2 ICD	At all point during treatment (as specified in the study schedule)
Adverse events of Grades 3 and 4	Throughout the study
Adverse events related to potential cardiotoxicity	Throughout the study
Solicited local and general signs and symptoms (recorded by the patients on diary cards)	During a period of four days following each administration of study vaccine
Unsolicited adverse events (serious and non-serious)	At any time during the study
Unsolicited serious adverse events	At any time during the study
Any documented toxicity	At any time during the study
Left ventricular ejection fraction	At screening and at appropriate intervals during treatment.
Laboratory values: hematological and biochemical variables (including coagulation).	at all point during treatment as specified in the study schedule
Vital signs.	at each administration
Electrocardiographic results	at the end of cycle 1 and cycle 2 and at first follow-up visit
Results of physical examination	At each visit

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14.

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2005
• Primary Completion (Actual): September 29, 2008
• Study Completion (Actual): September 29, 2009

Study Registration Dates

• First Submitted: August 31, 2005
• First Submitted That Met QC Criteria: August 31, 2005
• First Posted (Estimate): September 1, 2005

Study Record Updates

• Last Update Posted (Actual): December 27, 2019
• Last Update Submitted That Met QC Criteria: December 26, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: 100633; 2004-001120-20 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: IPD is available via the Clinical Study Data Request site (click on the link provided below)
• IPD Sharing Time Frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
• IPD Sharing Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Study Data/Documents

1. Informed Consent Form
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Statistical Analysis Plan
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Individual Participant Data Set
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Clinical Study Report
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Dataset Specification
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Study Protocol
   Information identifier: 100633
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register